# EDGAR Filing Document

**Accession Number:** 0001321834
**File Stem:** 0001493152-25-023596
**Filing Date:** 2025-11
**Character Count:** 16740
**Document Hash:** 3c145cd2d7c7f8b3cae177fd2824bb76
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-023596.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001493152-25-023596

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251114

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Q/C TECHNOLOGIES, INC.
- **CENTRAL INDEX KEY:** 0001321834
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36268
- **FILM NUMBER:** 251487695

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS
- **STREET 2:** SUITE 249
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 856-848-8698

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS
- **STREET 2:** SUITE 249
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TNF Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20240725

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MyMD Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20210420

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Akers Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20170413

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 14, 2025**

**Q/C Technologies, Inc.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36268** | **22-2983783** |
| (State or other jurisdiction <br> of incorporation) | (Commission <br> File No.) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **1185 Avenue of the Americas, Suite 249**<br>**New York, NY** | **10036** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(856) 848-8698**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, par value $0.001 per share | QCLS | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

As reported below under Item 5.07 of this Current Report on Form 8-K, on November 14, 2025, Q/C Technologies, Inc. (the "Company") reconvened a special meeting of stockholders which was adjourned from November 10, 2025 (the "Special Meeting"), at which the Company's stockholders approved the second amendment (the "Incentive Plan Amendment") to the Q/C Technologies, Inc. 2021 Equity Incentive Plan, as amended (the "Incentive Plan"), to increase the aggregate number of shares of common stock, par value $0.001 per share (the "Common Stock") available for the grant of awards under the Incentive Plan by 1,375,000, to a total of 1,400,000 shares of Common Stock.

For more information about the Incentive Plan Amendment, see the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 20, 2025 (the "Proxy Statement"), the relevant portions of which are incorporated herein by reference. The foregoing description of the Incentive Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Incentive Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 5.07 Submission of Matters to a Vote of Security Holders.** 

On November 14, 2025, the Company reconvened the Special Meeting. As of the close of business on September 18, 2025, the record date for the Special Meeting, there were (i) 2,052,974 shares of Common Stock outstanding and entitled to an aggregate of 2,052,974 votes, (ii) 72,992 shares of Series D Convertible Preferred Stock, par value $0.001 per share ("Series D Preferred Stock"), outstanding and entitled to an aggregate of 12 votes, (iii) 9,206 shares of Series G Convertible Preferred Stock, par value $0.001 per share ("Series G Preferred Stock"), outstanding and entitled to an aggregate of 40,860 votes after the application of the limitation on voting rights and the beneficial ownership limitations pursuant to the terms of the Series G Preferred Stock as set forth in the certificate of designations for the Series G Preferred Stock, (iv) 7,000 shares of Series H Convertible Preferred Stock, par value $0.001 per share ("Series H Preferred Stock"), outstanding and entitled to an aggregate of 357,045 votes after the application of the limitation on voting rights and the beneficial ownership limitations pursuant to the terms of the Series H Preferred Stock as set forth in the certificate of designations for the Series H Preferred Stock, (v) 747,362 shares of Series I Convertible Preferred Stock, par value $0.001 per share ("Series I Preferred Stock" and, together with the Series D Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, the "Preferred Stock"), outstanding and entitled to an aggregate of 357,048 votes after the application of the limitation on voting rights and the beneficial ownership limitations pursuant to the terms of the Series I Preferred Stock as set forth in the certificate of designations for the Series I Preferred Stock, constituting all of the eligible securities entitled to vote on the proposals described below, provided, however, that holders of the Company's Series I Preferred Stock and the holders of the Company's Series H Preferred Stock were not entitled to vote on the Issuance Proposal (as defined below). Holders of the Company's Common Stock and Preferred Stock with a total aggregate voting power of 1,129,053 votes were present in person or represented by proxy at the Special Meeting.

The matters described below were submitted to a vote of the holders of the Company's Common Stock and Preferred Stock at the Special Meeting. Each proposal is described in detail in the Company's Proxy Statement. All proposals were approved by the Company's stockholders.

1. Approval,
 for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of Common Stock (A) underlying (i) shares of Series
 H Preferred Stock and warrants (the "Investor Warrants") issued by the Company to investors pursuant to the terms of
 that certain Securities Purchase Agreement, dated as of September 2, 2025, by and among the Company and the investors party thereto,
 (ii) warrants issued by the Company pursuant to the terms of (a) that certain engagement letter, dated August 27, 2025, between the
 Company and Rodman & Renshaw LLC, and (b) that certain engagement letter dated August 28, 2025, between the Company and GP Nurmenkari
 Inc. (collectively, the "Placement Agent Warrants"), (iii) shares of Series I Preferred Stock, issued by the Company
 pursuant to that certain Membership Interest Purchase Agreement (the "MIPA"), dated as of September 2, 2025, by and among
 the Company, LPU Holdings LLC ("LPU") and the members of LPU identified on the signature pages attached thereto, and
 (iv) warrants issued by the Company pursuant to the terms of that certain consulting agreement, dated as of October 1, 2025, by and
 among the Company, James Altucher and Z-List Media, Inc. (the "Consulting Warrants" and, together with the Investor Warrants
 and Placement Agent Warrants, the "Warrants"), and (B) to be issued pursuant to (i) that certain engagement letter, dated
 as of August 31, 2025, by and between the Company and Palladium Capital Group, LLC (the "Advisory Shares"), and (ii)
 the MIPA upon the achievement of certain milestone events (such shares, the "Milestone Shares"), including shares of
 Common Stock issuable upon certain warrants to be issued upon achievement of such milestone events (the "Milestone Warrants"),
 in an amount equal to or in excess of 20% of the Company's Common Stock outstanding immediately prior to the issuance of such
 Series H Preferred Stock, Series I Preferred Stock, Warrants, Advisory Shares, Milestone Shares and Milestone Warrants (including
 any issuance of shares of Common Stock upon the operation of anti-dilution provisions applicable to the Series H Preferred
 Stock, Series I Preferred Stock and Warrants in accordance with their terms) (the "Issuance Proposal").

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 598427 | 52744 | 455 | 477427 |

---

2. Approval
 of the Incentive Plan Amendment to increase the total number of shares of the Company's Common Stock authorized for issuance
 under such plan by 1,375,000, to a total of 1,400,000 shares of Common Stock (the "Incentive Plan Amendment Proposal").

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 592431 | 58891 | 304 | 477427 |

---

3. Approval
 of an amendment to the Company's Certificate of Incorporation, as amended (the "Charter"), to effect, at the discretion
 of the board of directors (the "Board") of the Company but prior to the one-year anniversary of the date on which the
 reverse stock split is approved by the Company's stockholders at the Special Meeting, a reverse stock split of all of the outstanding
 shares of Common Stock, at a ratio in the range of 1-for-2 to 1-for-250, with such ratio to be determined by the Board in its discretion
 and included in a public announcement (the "Reverse Stock Split Proposal").

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 998290 | 129096 | 1667 |

---

4. Approval
 of a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation
 and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of any one
 or more of the proposals presented at the Special Meeting.

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 1001603 | 106352 | 21098 |

---

For more information about the foregoing proposals, see the Proxy Statement, the relevant portions of which are incorporated herein by reference. The results reported above are final voting results. No other matters were considered or voted upon at the Special Meeting.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit <br> Number** | **Description** |
| 10.1 | [Second Amendment to the Q/C Technologies, Inc. 2021 Equity Incentive Plan.](ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Q/C TECHNOLOGIES, INC.** | **Q/C TECHNOLOGIES, INC.** |
| Date: November 14, 2025 | By: | */s/ Joshua Silverman* |
|  | Name: | Joshua Silverman |
|  | Title: | Executive Chairman |

---

## Exhibit 10.1

**Exhibit 10.1**

**SECOND AMENDMENT TO<br> q/c technologies, Inc. 2021 Equity Incentive Plan**

This SECOND AMENDMENT TO Q/C TECHNOLOGIES, Inc. 2021 Equity Incentive Plan (this "***Amendment***"), effective as of November 14, 2025, is made and entered into by Q/C Technologies, Inc., a Delaware corporation (the "***Company***"). Terms used in this Amendment with initial capital letters that are not otherwise defined herein shall have the meanings ascribed to such terms in the Q/C Technologies 2021 Equity Incentive Plan, as amended (the "***Plan***").

**RECITALS**

**WHEREAS**, the Company sponsors and maintains the Plan in order to attract and retain the services of key employees, contractors, and outside directors of the Company and its subsidiaries;

**WHEREAS**, Article 9 of the Plan provides that the Board of Directors of the Company (the "***Board***") may amend the Plan at any time and from time to time without the consent of the Participants, provided that the Board shall not amend the Plan without stockholder approval if such approval is required in order to comply with the Code or any other applicable law, or to comply with the applicable stock exchange requirements;

**WHEREAS**, the Board desires to amend the Plan to increase the maximum number of shares of Common Stock that may be issued under the Plan, as set forth in Section 5.1 of the Plan, by an additional 1,375,000 shares of Common Stock; and

**WHEREAS**, the Board intends to submit this Amendment to the Company's stockholders for their approval in accordance with Article 9 of the Plan.

**NOW, THEREFORE**, in accordance with Article 9 of the Plan, and subject to the approval of the Company's stockholders, the Company hereby amends the Plan, effective as of the date hereof, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Section 5.1 of the Plan is hereby amended by deleting said section in its entirety and substituting in lieu thereof the following new Section 5.1:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 **Number Available for Awards**. Subject to adjustment as provided in <u>Articles 11 and 12</u>, the maximum number of shares of Common Stock that may be delivered pursuant to Awards granted under the Plan is one million four hundred thousand (1,400,000) shares, of which one hundred percent (100%) may be delivered pursuant to Incentive Stock Options. Shares to be issued may be made available from authorized but unissued Common Stock, Common Stock held by the Company in its treasury, or Common Stock purchased by the Company on the open market or otherwise. During the term of this Plan, the Company will at all times reserve and keep available the number of shares of Common Stock that shall be sufficient to satisfy the requirements of this Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. This Amendment shall be effective on the date first set forth above. In the event stockholder approval of this Amendment is not obtained within twelve (12) months of the date the Board approved this Amendment, the additional shares added to the Plan pursuant to this Amendment shall not be available for grant as Incentive Stock Options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Except as expressly amended by this Amendment, the Plan shall continue in full force and effect in accordance with the provisions thereof.

[*Signature page follows.*]

**IN WITNESS WHEREOF**, the Company has caused this Amendment to be duly executed as of the date first written above.

---

| | |
|:---|:---|
| **Q/C Technologies, Inc.** | **Q/C Technologies, Inc.** |
| By: | */s/ Joshua Silverman* |
| Name: | Joshua Silverman |
| Title: | Executive Chairman |

---